期刊文献+

干扰素2α联合力尔凡治疗转移性肾癌 被引量:2

United Treatment of Lifein and Interferon-2α in Metastatic Renal Carcinoma
下载PDF
导出
摘要 目的探讨干扰素2α联合力尔凡治疗转移性肾癌的疗效。方法对18例转移性肾癌患者应用干扰素2α300万U/次,每周3次。第5周开始联合力尔凡治疗,5.0 mg/d,皮下注射,连用5 d,然后给予10 mg/d,静滴,连用25 d,2个月为1疗程,至少2个疗程。结果随访5~38个月,完全缓解1例,部分缓解7例,病灶无变化3例,病灶进展7例。缓解病例均为透明细胞癌。结论干扰素联合力尔凡治疗转移性肾癌,能缓解症状,延长生存期。 Objective To investigate the effect of interferon-2α combined with Lifein in the treatment of metastatic renal carcinoma.Methods 18 cases of such patients were treated with interferon-2α,300 million U per times,3 times a week.Lifein united treatment after 5 weeks,5.0 mg/d subcutaneously,for 5 d,then 10 mg/d intravenously,once every 25 d,2 months,1 course of treatment,at least 2 courses.Results The cases were followed-up 5 to 38 months.1 case was complete remission,partial remission in 7 cases,the lesions did not change in 3 cases,7 cases of disease progression.All catabatic cases were clear cell carcinoma.Conclusion United treatment of interferon-2α and Lifein,can relieve symptoms and prolong survival in metastatic renal carcinoma.
机构地区 黑龙江省医院
出处 《黑龙江医学》 2011年第5期352-353,共2页 Heilongjiang Medical Journal
关键词 干扰素 力尔凡 肾肿瘤 预后 Interferon Lifein Kidney neoplasms Prognosis
  • 相关文献

参考文献8

  • 1钟华,顾方六.肾癌生物治疗的现状和前景[J].中华泌尿外科杂志,1996,17(9):560-563. 被引量:10
  • 2Yagoda A,Abi-Rached B,Petrylak D.Chemotherapy for advanced renal cell carcinoma[J].Semin Oncol,1995,22:42-46.
  • 3Ramsay J.Immunotherapy and chemotherapy for carcinoma of the Kidney[J].Br J Urol,1992,70:465-468.
  • 4袁孔华,樊国荣,燕美玉,李立新,黄循.肾癌患者手术治疗前后细胞免疫功能变化的观察[J].临床泌尿外科杂志,1994,9(1):44-45. 被引量:7
  • 5罗海波,朱平,李兰娟.细菌霉素与临床[M].北京:人民卫生出版社,1999:39.
  • 6闻玉梅.现代微生物学[M].上海:上海医科大学出版社,1999.890.
  • 7江明性,新编使用药物学[M].北京:科学出版社,2000:198.
  • 8Pyrhoenen S,Salminen E,Lehtonen T,et al.Recombinant interferonalfa-la with vinblastine vs vinblastine alone in advanced renal cell carcinoma.A phase Ⅲ study Abstract[J].Proc Am Soc Clin Oncol,1996,15:244.

共引文献21

同被引文献56

  • 1王欢,周芳坚,王其京,秦自科,黄丽惜,刘卓炜,韩辉,李永强,陈诗萍,夏建川.负载自体肿瘤细胞裂解物的DC疫苗联合CIK治疗晚期肾癌的临床观察——附10例报告[J].癌症,2006,25(5):625-630. 被引量:51
  • 2Sugawara E, Togashi Y, Kuroda N, et al. Identification of ana-plastic lymphoma kinase fusions in renal cancer : Large-scale im-munohistochemical screening by the intercalated antibody-en-hanced polymer method [ J ]. Cancer, 2012,118(18): 4427-4436.
  • 3Nepple KG, Yang L, Grubb RR, et al. Population based analysisof the increasing incidence of kidney cancer in the United States :Evaluation of age specific trends from 1975 to 2006 [J]. J Urol,2012,187(1) : 32-38.
  • 4Vrdoljak E, Ciuleanu T, Kharkevich G, et al. Optimizing treat-ment for patients with metastatic renal cell carcinoma in the Centraland Eastern European region [ J ]. Expert Opin Pharmacother,2012,13(2) : 159-174.
  • 5Cohen HT, Mcgovem FJ. Renal-cell carcinoma [J]. N Engl jMed, 2005,353(23) : 2477-2490.
  • 6Rosenberg S A. Gene therapy for cancer [ J]. JAMA,1992,268(17) : 2416-2419.
  • 7Li M, Xu T, Zhang Z,et al. Phase II multicenter, randomized,double-blind study of recombinant mutated human tumor necrosisfactor-a in combination with chemotherapies in cancer patients[J]. Cancer Sci, 2012, 103(2) : 288-295.
  • 8Shiba M,Nonomura N, Nakai Y, et al. Type*! interferon receptorexpression : Its circadian rhythm and downregulation after interfer-on-alpha administration in peripheral blood cells from renal cancerpatients [J]. Int J Urol, 2009,16(4) : 356-359.
  • 9Escudier B, Bellmunt J, Negrier S, et al. Phase ID trial of bev-acizumab plus interferon alfa-2a in patients with metastatic renalcell carcinoma ( AVOREN ) : Final analysis of overall survival[J]. J Clin Oncol, 2010, 28(13) : 2144-2150.
  • 10Rini BI, Halabi S’ Rosenberg JE, et al. Phase ffl trial of bevaci-zumab plus interferon alfa versus interferon alfa monotherapy in pa-tients with metastatic renal cell carcinoma : Final results of CALGB90206 [J]. J Clin Oncol, 2010, 28(13) : 2137-2143.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部